This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma.
A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
AbGn-107 is an antibody drug conjugate (ADC) which targets an antigen (AG7 antigen) present in gastric, colorectal, and pancreatic cancer. This study is a standard 3 + 3 dose escalation design with cohort expansion. AbGn-107 will be administered every 28 days in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma. The primary objectives of this study are to define the safety profile and to determine the maximum tolerated dose (MTD), and the secondary objectives are to evaluate the pharmacokinetic (PK) parameters, the immunogenicity, and preliminary efficacy.
Gastric, Colorectal, and Pancreatic Adenocarcinoma Cancer Antibody Drug Conjugate AbGn-107 Adenocarcinoma Gastric Colorectal Pancreatic
Open to people ages 18 years and up
Chemo-refractory is defined as:
Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02908451.
© 2017 The Regents of the University of California